(RS)-3,4,5-THPG
Discontinued Product
Unfortunately (RS)-3,4,5-THPG (Cat. No. 1012) has been withdrawn from sale for commercial reasons.
Biological Activity
First antagonist of mGlu6, the group III mGlu receptor found in the retina.
Technical Data
| M. Wt | 199.1636 |
| Storage | Desiccate at -20°C |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Product Datasheets
Please contact Customer Service.
References
References are publications that support the products' biological activity.
Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493 PMID: 8730745
Thoreson et al (1997) Two phenylglycine derivatives antagonize responses to L-AP4 in ON bipolar cells of the amphibian retina. Neuropharmacology 36 1 PMID: 9144636
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group III Receptor Antagonists
Keywords: (RS)-3,4,5-THPG, supplier, Glutamate, (Metabotropic), Group, III, Receptors, Glutamate, (Metabotropic), Group, III, Receptors, Tocris Bioscience
Citations for (RS)-3,4,5-THPG
Citations are publications that use Tocris products.
Currently there are no citations for (RS)-3,4,5-THPG.
Reviews for (RS)-3,4,5-THPG
There are currently no reviews for this product. Be the first to review (RS)-3,4,5-THPG and earn rewards!
Have you used (RS)-3,4,5-THPG?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and Europe
Submit a ReviewLiterature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GPCR Product Listing
A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:
- Rhodopsin-like Receptors
- Secretin-like Receptors
- Glutamate Receptors
- Frizzled Receptors
- GPCR Signaling
Pain Research Product Guide
A collection of over 250 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia Poster
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.
